A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication

Trial Profile

A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2017

At a glance

  • Drugs Evenamide (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Newron Pharmaceuticals
  • Most Recent Events

    • 25 Mar 2017 Results presented at the 16th International Congress on Schizophrenia Research 2017, according to a Newron Pharmaceuticals media release.
    • 25 Mar 2017 Results published in a Newron Pharmaceuticals media release.
    • 13 Mar 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top